Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology

P. Fabbrini, K. Finkel, M. Gallieni, G. Capasso, M. Cavo, A. Santoro, S. Pasquali

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Acute kidney injury (AKI) is a frequent complication of multiple myeloma and is associated with increased short-term mortality. Additionally, even a single episode of AKI can eventually lead to end-stage renal disease (ESRD), significantly reducing quality of life and long-term survival. In the setting of multiple myeloma, severe AKI (requiring dialysis) is typically secondary to cast nephropathy (CN). Renal injury in CN is due to intratubular obstruction from precipitation of monoclonal serum free light chains (sFLC) as well as direct tubular toxicity of sFLC via stimulation of nuclear factor (NF)κB inflammatory pathways. Current mainstays of CN treatment are early removal of precipitating factors such as nephrotoxic drugs, acidosis and dehydration, together with rapid reduction of sFLC levels. Introduction of the proteasome inhibitor bortezomib has significantly improved the response rates in multiple myeloma due to its ability to rapidly reduce sFLC levels and has been referred to as “renoprotective” therapy. As an adjunct to chemotherapy, several new extracorporeal techniques have raised interest as a further means to reduce sFLC concentrations in the treatment of CN. Whether addition of extracorporeal therapies to renoprotective therapy can result in better renal recovery is still a matter of debate and there are currently no guidelines in this field. In this positon paper, we offer an overview of the available data and the authors’ perspectives on extracorporeal treatments in CN.

Original languageEnglish
Pages (from-to)735-746
Number of pages12
JournalJournal of Nephrology
Volume29
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Nephrology
Multiple Myeloma
Acute Kidney Injury
Light
Serum
Therapeutics
Kidney
Precipitating Factors
Proteasome Inhibitors
Acidosis
Dehydration
Chronic Kidney Failure
Dialysis
Quality of Life
Guidelines
Drug Therapy
Mortality
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Acute kidney injury (AKI)
  • Cast nephropathy
  • Dialysis
  • Multiple myeloma
  • Serum free light chains (sFLC)

ASJC Scopus subject areas

  • Nephrology

Cite this

Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma : a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. / Fabbrini, P.; Finkel, K.; Gallieni, M.; Capasso, G.; Cavo, M.; Santoro, A.; Pasquali, S.

In: Journal of Nephrology, Vol. 29, No. 6, 01.12.2016, p. 735-746.

Research output: Contribution to journalArticle

Fabbrini, P. ; Finkel, K. ; Gallieni, M. ; Capasso, G. ; Cavo, M. ; Santoro, A. ; Pasquali, S. / Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma : a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. In: Journal of Nephrology. 2016 ; Vol. 29, No. 6. pp. 735-746.
@article{dfd611560ec8420d8c89acbb39b8e92f,
title = "Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology",
abstract = "Acute kidney injury (AKI) is a frequent complication of multiple myeloma and is associated with increased short-term mortality. Additionally, even a single episode of AKI can eventually lead to end-stage renal disease (ESRD), significantly reducing quality of life and long-term survival. In the setting of multiple myeloma, severe AKI (requiring dialysis) is typically secondary to cast nephropathy (CN). Renal injury in CN is due to intratubular obstruction from precipitation of monoclonal serum free light chains (sFLC) as well as direct tubular toxicity of sFLC via stimulation of nuclear factor (NF)κB inflammatory pathways. Current mainstays of CN treatment are early removal of precipitating factors such as nephrotoxic drugs, acidosis and dehydration, together with rapid reduction of sFLC levels. Introduction of the proteasome inhibitor bortezomib has significantly improved the response rates in multiple myeloma due to its ability to rapidly reduce sFLC levels and has been referred to as “renoprotective” therapy. As an adjunct to chemotherapy, several new extracorporeal techniques have raised interest as a further means to reduce sFLC concentrations in the treatment of CN. Whether addition of extracorporeal therapies to renoprotective therapy can result in better renal recovery is still a matter of debate and there are currently no guidelines in this field. In this positon paper, we offer an overview of the available data and the authors’ perspectives on extracorporeal treatments in CN.",
keywords = "Acute kidney injury (AKI), Cast nephropathy, Dialysis, Multiple myeloma, Serum free light chains (sFLC)",
author = "P. Fabbrini and K. Finkel and M. Gallieni and G. Capasso and M. Cavo and A. Santoro and S. Pasquali",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s40620-016-0347-9",
language = "English",
volume = "29",
pages = "735--746",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer International Publishing",
number = "6",

}

TY - JOUR

T1 - Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma

T2 - a position statement of the Onconephrology Work Group of the Italian Society of Nephrology

AU - Fabbrini, P.

AU - Finkel, K.

AU - Gallieni, M.

AU - Capasso, G.

AU - Cavo, M.

AU - Santoro, A.

AU - Pasquali, S.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Acute kidney injury (AKI) is a frequent complication of multiple myeloma and is associated with increased short-term mortality. Additionally, even a single episode of AKI can eventually lead to end-stage renal disease (ESRD), significantly reducing quality of life and long-term survival. In the setting of multiple myeloma, severe AKI (requiring dialysis) is typically secondary to cast nephropathy (CN). Renal injury in CN is due to intratubular obstruction from precipitation of monoclonal serum free light chains (sFLC) as well as direct tubular toxicity of sFLC via stimulation of nuclear factor (NF)κB inflammatory pathways. Current mainstays of CN treatment are early removal of precipitating factors such as nephrotoxic drugs, acidosis and dehydration, together with rapid reduction of sFLC levels. Introduction of the proteasome inhibitor bortezomib has significantly improved the response rates in multiple myeloma due to its ability to rapidly reduce sFLC levels and has been referred to as “renoprotective” therapy. As an adjunct to chemotherapy, several new extracorporeal techniques have raised interest as a further means to reduce sFLC concentrations in the treatment of CN. Whether addition of extracorporeal therapies to renoprotective therapy can result in better renal recovery is still a matter of debate and there are currently no guidelines in this field. In this positon paper, we offer an overview of the available data and the authors’ perspectives on extracorporeal treatments in CN.

AB - Acute kidney injury (AKI) is a frequent complication of multiple myeloma and is associated with increased short-term mortality. Additionally, even a single episode of AKI can eventually lead to end-stage renal disease (ESRD), significantly reducing quality of life and long-term survival. In the setting of multiple myeloma, severe AKI (requiring dialysis) is typically secondary to cast nephropathy (CN). Renal injury in CN is due to intratubular obstruction from precipitation of monoclonal serum free light chains (sFLC) as well as direct tubular toxicity of sFLC via stimulation of nuclear factor (NF)κB inflammatory pathways. Current mainstays of CN treatment are early removal of precipitating factors such as nephrotoxic drugs, acidosis and dehydration, together with rapid reduction of sFLC levels. Introduction of the proteasome inhibitor bortezomib has significantly improved the response rates in multiple myeloma due to its ability to rapidly reduce sFLC levels and has been referred to as “renoprotective” therapy. As an adjunct to chemotherapy, several new extracorporeal techniques have raised interest as a further means to reduce sFLC concentrations in the treatment of CN. Whether addition of extracorporeal therapies to renoprotective therapy can result in better renal recovery is still a matter of debate and there are currently no guidelines in this field. In this positon paper, we offer an overview of the available data and the authors’ perspectives on extracorporeal treatments in CN.

KW - Acute kidney injury (AKI)

KW - Cast nephropathy

KW - Dialysis

KW - Multiple myeloma

KW - Serum free light chains (sFLC)

UR - http://www.scopus.com/inward/record.url?scp=84992451550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992451550&partnerID=8YFLogxK

U2 - 10.1007/s40620-016-0347-9

DO - 10.1007/s40620-016-0347-9

M3 - Article

AN - SCOPUS:84992451550

VL - 29

SP - 735

EP - 746

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 6

ER -